SCRA awarded the Medical University of South Carolina $870,000. MUSC has $397,000 in matching funds for a total of over one million dollars to bring three innovations into the marketplace. They include a recombinant protein cancer vaccine, an antibiotic-eluting implant device, and a burn wound gel. The project will also connect MUSC investigators with companies across the state to create strategic academic-industry collaborations. The College of Charleston, Furman University, and Wofford College are working with MUSC on the projects. The industry partners are Pearl Biologics of Daniel Island, SC, Parimer Scientific (SCRA Member Company) of Easley, SC, and Leukogene Therapeutics (SCRA Member Company), based at MUSC.
